Gabapentin

A Ca2+ channel α2-δ ligand far beyond epilepsy therapy

Pasquale Striano, Salvatore Striano

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter γ-aminobutyric acid (GABA). However, its principal proposed mechanism of action is the interaction with the α2-δ subunit of L-type voltage-regulated calcium channels. Gabapentin possesses several desirable pharmacokinetic properties, along with few drug interactions, particularly with other AEDs. These properties make it a well-tolerated drug, with the most commonly reported adverse events being somnolence and dizziness. Gabapentin is one of the new first-generation AEDs that expanded its use into a broad range of neurologic and psychiatric disorders shortly after it was licensed in 1993 for use in drug-resistant partial epilepsy with or without secondary generalization. Nowadays, most worldwide prescriptions for gabapentin are for conditions other than epilepsy, especially the treatment of chronic pain of different etiologies. This article will review the pharmacology, mechanism of action, drug interactions and adverse effects of gabapentin. In addition, the clinical trial data, cost analysis and recommended schedule of administration, are also reviewed.

Original languageEnglish
Pages (from-to)353-368
Number of pages16
JournalDrugs of Today
Volume44
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Epilepsy
Ligands
Drug Interactions
Aminobutyrates
Therapeutics
Partial Epilepsy
Drug Design
Dizziness
Calcium Channels
Nervous System Diseases
Chronic Pain
Anticonvulsants
gamma-Aminobutyric Acid
Prescriptions
Neurotransmitter Agents
Psychiatry
Appointments and Schedules
Pharmacokinetics
gabapentin
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Gabapentin : A Ca2+ channel α2-δ ligand far beyond epilepsy therapy. / Striano, Pasquale; Striano, Salvatore.

In: Drugs of Today, Vol. 44, No. 5, 05.2008, p. 353-368.

Research output: Contribution to journalArticle

Striano, Pasquale ; Striano, Salvatore. / Gabapentin : A Ca2+ channel α2-δ ligand far beyond epilepsy therapy. In: Drugs of Today. 2008 ; Vol. 44, No. 5. pp. 353-368.
@article{b62f8d2233d44807a924b3416d0e980a,
title = "Gabapentin: A Ca2+ channel α2-δ ligand far beyond epilepsy therapy",
abstract = "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter γ-aminobutyric acid (GABA). However, its principal proposed mechanism of action is the interaction with the α2-δ subunit of L-type voltage-regulated calcium channels. Gabapentin possesses several desirable pharmacokinetic properties, along with few drug interactions, particularly with other AEDs. These properties make it a well-tolerated drug, with the most commonly reported adverse events being somnolence and dizziness. Gabapentin is one of the new first-generation AEDs that expanded its use into a broad range of neurologic and psychiatric disorders shortly after it was licensed in 1993 for use in drug-resistant partial epilepsy with or without secondary generalization. Nowadays, most worldwide prescriptions for gabapentin are for conditions other than epilepsy, especially the treatment of chronic pain of different etiologies. This article will review the pharmacology, mechanism of action, drug interactions and adverse effects of gabapentin. In addition, the clinical trial data, cost analysis and recommended schedule of administration, are also reviewed.",
author = "Pasquale Striano and Salvatore Striano",
year = "2008",
month = "5",
doi = "10.1358/dot.2008.44.5.1186403",
language = "English",
volume = "44",
pages = "353--368",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Gabapentin

T2 - A Ca2+ channel α2-δ ligand far beyond epilepsy therapy

AU - Striano, Pasquale

AU - Striano, Salvatore

PY - 2008/5

Y1 - 2008/5

N2 - Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter γ-aminobutyric acid (GABA). However, its principal proposed mechanism of action is the interaction with the α2-δ subunit of L-type voltage-regulated calcium channels. Gabapentin possesses several desirable pharmacokinetic properties, along with few drug interactions, particularly with other AEDs. These properties make it a well-tolerated drug, with the most commonly reported adverse events being somnolence and dizziness. Gabapentin is one of the new first-generation AEDs that expanded its use into a broad range of neurologic and psychiatric disorders shortly after it was licensed in 1993 for use in drug-resistant partial epilepsy with or without secondary generalization. Nowadays, most worldwide prescriptions for gabapentin are for conditions other than epilepsy, especially the treatment of chronic pain of different etiologies. This article will review the pharmacology, mechanism of action, drug interactions and adverse effects of gabapentin. In addition, the clinical trial data, cost analysis and recommended schedule of administration, are also reviewed.

AB - Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter γ-aminobutyric acid (GABA). However, its principal proposed mechanism of action is the interaction with the α2-δ subunit of L-type voltage-regulated calcium channels. Gabapentin possesses several desirable pharmacokinetic properties, along with few drug interactions, particularly with other AEDs. These properties make it a well-tolerated drug, with the most commonly reported adverse events being somnolence and dizziness. Gabapentin is one of the new first-generation AEDs that expanded its use into a broad range of neurologic and psychiatric disorders shortly after it was licensed in 1993 for use in drug-resistant partial epilepsy with or without secondary generalization. Nowadays, most worldwide prescriptions for gabapentin are for conditions other than epilepsy, especially the treatment of chronic pain of different etiologies. This article will review the pharmacology, mechanism of action, drug interactions and adverse effects of gabapentin. In addition, the clinical trial data, cost analysis and recommended schedule of administration, are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=51649114823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649114823&partnerID=8YFLogxK

U2 - 10.1358/dot.2008.44.5.1186403

DO - 10.1358/dot.2008.44.5.1186403

M3 - Article

VL - 44

SP - 353

EP - 368

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 5

ER -